-
Anup
Agarwal,
A.
Mukherjee,
G.
Kumar,
P.
Chatterjee,
T.
Bhatnagar,
P.
Malhotra
(2020)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
The BMJ, 371
-
A.
Omrani,
Ahmed
Zaqout,
A.
Baiou,
J.
Daghfal,
N.
Elkum,
R.
Alattar,
D.
Bakdach,
H.
Abusriwil,
Abdalrahman
Mostafa,
B.
Alhariri,
Naseem
Ambra,
M.
Khatib,
Ali
Eldeeb,
Zeyd
Merenkov,
Z.
Fawzi,
Saloua
Hmissi,
A.
Hssain,
P.
Coyle,
H.
Alsoub,
M.
Almaslamani,
A.
Alkhal
(2020)
Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report
Journal of Medical Virology, 93
-
M.
Erkurt,
A.
Sarici,
İ.
Berber,
I.
Kuku,
E.
Kaya,
M.
Özgül
(2020)
Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia
Transfusion and Apheresis Science, 59
-
(
FlexnerS
LewisPA
. Experimental poliomyelitis in monkeyseighth note: further contributions to the subjects of immunization and serum therapy. J Am Med Assoc. 1910;55(8):662–663. doi:10.1001/jama.1910.04330080028014)
FlexnerS
LewisPA
. Experimental poliomyelitis in monkeyseighth note: further contributions to the subjects of immunization and serum therapy. J Am Med Assoc. 1910;55(8):662–663. doi:10.1001/jama.1910.04330080028014
FlexnerS
LewisPA
. Experimental poliomyelitis in monkeyseighth note: further contributions to the subjects of immunization and serum therapy. J Am Med Assoc. 1910;55(8):662–663. doi:10.1001/jama.1910.04330080028014,
FlexnerS
LewisPA
. Experimental poliomyelitis in monkeyseighth note: further contributions to the subjects of immunization and serum therapy. J Am Med Assoc. 1910;55(8):662–663. doi:10.1001/jama.1910.04330080028014
-
(
MadariagaML
SchrantzS
JansenMO
, et al. Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical Center (5/7/2020). Available at
10.2139/ssrn.3605131)
MadariagaML
SchrantzS
JansenMO
, et al. Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical Center (5/7/2020). Available at
10.2139/ssrn.3605131
MadariagaML
SchrantzS
JansenMO
, et al. Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical Center (5/7/2020). Available at
10.2139/ssrn.3605131,
MadariagaML
SchrantzS
JansenMO
, et al. Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical Center (5/7/2020). Available at
10.2139/ssrn.3605131
-
(
KakuturuJ.
McCluskeyC.
CaseyF.L.
CicekS.
HayangaJ.A
. Extracorporeal membrane oxygenation to treat a 15-year-old patient with severe coronavirus disease 2019 (COVID-19) respiratory failure. JTCVS techniques. 2021;Jun(7):265–266. doi:10.1016/j.xjtc.2021.03.012)
KakuturuJ.
McCluskeyC.
CaseyF.L.
CicekS.
HayangaJ.A
. Extracorporeal membrane oxygenation to treat a 15-year-old patient with severe coronavirus disease 2019 (COVID-19) respiratory failure. JTCVS techniques. 2021;Jun(7):265–266. doi:10.1016/j.xjtc.2021.03.012
KakuturuJ.
McCluskeyC.
CaseyF.L.
CicekS.
HayangaJ.A
. Extracorporeal membrane oxygenation to treat a 15-year-old patient with severe coronavirus disease 2019 (COVID-19) respiratory failure. JTCVS techniques. 2021;Jun(7):265–266. doi:10.1016/j.xjtc.2021.03.012,
KakuturuJ.
McCluskeyC.
CaseyF.L.
CicekS.
HayangaJ.A
. Extracorporeal membrane oxygenation to treat a 15-year-old patient with severe coronavirus disease 2019 (COVID-19) respiratory failure. JTCVS techniques. 2021;Jun(7):265–266. doi:10.1016/j.xjtc.2021.03.012
-
(
AbolghasemiH
EshghiP
CheraghaliAM
, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102875. doi:10.1016/j.transci.2020.102875)
AbolghasemiH
EshghiP
CheraghaliAM
, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102875. doi:10.1016/j.transci.2020.102875
AbolghasemiH
EshghiP
CheraghaliAM
, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102875. doi:10.1016/j.transci.2020.102875,
AbolghasemiH
EshghiP
CheraghaliAM
, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102875. doi:10.1016/j.transci.2020.102875
-
Zunyou
Wu,
J.
McGoogan
(2020)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA
-
(
AlsharidahS
AyedM
AmeenRM
, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Feb;103:439–446. doi:10.1016/j.ijid.2020.11.198)
AlsharidahS
AyedM
AmeenRM
, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Feb;103:439–446. doi:10.1016/j.ijid.2020.11.198
AlsharidahS
AyedM
AmeenRM
, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Feb;103:439–446. doi:10.1016/j.ijid.2020.11.198,
AlsharidahS
AyedM
AmeenRM
, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Feb;103:439–446. doi:10.1016/j.ijid.2020.11.198
-
D.
Ibrahim,
L.
Dulipsingh,
Lisa
Zapatka,
Reginald
Eadie,
R.
Crowell,
K.
Williams,
Dorothy
Wakefield,
L.
Cook,
Jennifer
Puff,
S.
Hussain
(2020)
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Infectious diseases and therapy
-
A.
Chan,
A.
Rout
(2020)
Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19
Journal of Clinical Medicine Research, 12
-
(
AgarwalA
MukherjeeA
KumarG
ChatterjeeP
BhatnagarT
MalhotraP
. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020 Oct 22;371:m3939. doi:10.1136/bmj.m3939. Erratum in: BMJ. 2020 Nov 3;371:m4232. PMID: 33093056; PMCID: PMC7578662.)
AgarwalA
MukherjeeA
KumarG
ChatterjeeP
BhatnagarT
MalhotraP
. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020 Oct 22;371:m3939. doi:10.1136/bmj.m3939. Erratum in: BMJ. 2020 Nov 3;371:m4232. PMID: 33093056; PMCID: PMC7578662.
AgarwalA
MukherjeeA
KumarG
ChatterjeeP
BhatnagarT
MalhotraP
. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020 Oct 22;371:m3939. doi:10.1136/bmj.m3939. Erratum in: BMJ. 2020 Nov 3;371:m4232. PMID: 33093056; PMCID: PMC7578662.,
AgarwalA
MukherjeeA
KumarG
ChatterjeeP
BhatnagarT
MalhotraP
. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020 Oct 22;371:m3939. doi:10.1136/bmj.m3939. Erratum in: BMJ. 2020 Nov 3;371:m4232. PMID: 33093056; PMCID: PMC7578662.
-
M.
Madariaga,
D.
Shaw,
J.
Kress,
K.
Shanmugarajah,
John
Fung,
P.
Wilson,
J.
Alverdy
(2020)
Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical Center
-
(
ZhouF
YuT
DuR
, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3)
ZhouF
YuT
DuR
, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
ZhouF
YuT
DuR
, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3,
ZhouF
YuT
DuR
, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
-
(
SahuKK
MishraAK
MartinK
ChastainI
. COVID-19 and restrictive lung disease: a deadly combo to trip off the fine balance. Monaldi Arch Chest Dis = Arch Monaldi per le Mal del Torace. 2020 Jun 29;90(2):395–397. doi:10.4081/monaldi.2020.1346)
SahuKK
MishraAK
MartinK
ChastainI
. COVID-19 and restrictive lung disease: a deadly combo to trip off the fine balance. Monaldi Arch Chest Dis = Arch Monaldi per le Mal del Torace. 2020 Jun 29;90(2):395–397. doi:10.4081/monaldi.2020.1346
SahuKK
MishraAK
MartinK
ChastainI
. COVID-19 and restrictive lung disease: a deadly combo to trip off the fine balance. Monaldi Arch Chest Dis = Arch Monaldi per le Mal del Torace. 2020 Jun 29;90(2):395–397. doi:10.4081/monaldi.2020.1346,
SahuKK
MishraAK
MartinK
ChastainI
. COVID-19 and restrictive lung disease: a deadly combo to trip off the fine balance. Monaldi Arch Chest Dis = Arch Monaldi per le Mal del Torace. 2020 Jun 29;90(2):395–397. doi:10.4081/monaldi.2020.1346
-
(
JoynerMJ
WrightRS
FairweatherD
, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. doi:10.1172/JCI14020032525844)
JoynerMJ
WrightRS
FairweatherD
, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. doi:10.1172/JCI14020032525844
JoynerMJ
WrightRS
FairweatherD
, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. doi:10.1172/JCI14020032525844,
JoynerMJ
WrightRS
FairweatherD
, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. doi:10.1172/JCI14020032525844
-
(
ShenoyAG
HettingerAZ
FernandezSJ
BlumenthalJ
BaezV
. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. doi:10.1111/bjh.1727233482025)
ShenoyAG
HettingerAZ
FernandezSJ
BlumenthalJ
BaezV
. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. doi:10.1111/bjh.1727233482025
ShenoyAG
HettingerAZ
FernandezSJ
BlumenthalJ
BaezV
. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. doi:10.1111/bjh.1727233482025,
ShenoyAG
HettingerAZ
FernandezSJ
BlumenthalJ
BaezV
. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. doi:10.1111/bjh.1727233482025
-
(
IbrahimD
DulipsinghL
ZapatkaL
, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther. 2020 Dec;9(4):913-926. doi:10.1007/s40121-020-00341-2)
IbrahimD
DulipsinghL
ZapatkaL
, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther. 2020 Dec;9(4):913-926. doi:10.1007/s40121-020-00341-2
IbrahimD
DulipsinghL
ZapatkaL
, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther. 2020 Dec;9(4):913-926. doi:10.1007/s40121-020-00341-2,
IbrahimD
DulipsinghL
ZapatkaL
, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther. 2020 Dec;9(4):913-926. doi:10.1007/s40121-020-00341-2
-
(
ChanAS
RoutA
. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448–453. doi:10.14740/jocmr424032655740)
ChanAS
RoutA
. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448–453. doi:10.14740/jocmr424032655740
ChanAS
RoutA
. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448–453. doi:10.14740/jocmr424032655740,
ChanAS
RoutA
. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448–453. doi:10.14740/jocmr424032655740
-
K.
Sahu,
A.
Mishra,
K.
Martin,
I.
Chastain
(2020)
COVID-19 and restrictive lung disease: A deadly combo to trip off the fine balance.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 90 2
-
(
Klassen SA, Senefeld JW, Johnson PW, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262–1275. doi:10.1016/j.mayocp.2021.02.008
)
Klassen SA, Senefeld JW, Johnson PW, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262–1275. doi:10.1016/j.mayocp.2021.02.008
Klassen SA, Senefeld JW, Johnson PW, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262–1275. doi:10.1016/j.mayocp.2021.02.008
,
Klassen SA, Senefeld JW, Johnson PW, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262–1275. doi:10.1016/j.mayocp.2021.02.008
-
(
ShenC
WangZ
ZhaoF
, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.478332219428)
ShenC
WangZ
ZhaoF
, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.478332219428
ShenC
WangZ
ZhaoF
, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.478332219428,
ShenC
WangZ
ZhaoF
, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.478332219428
-
A.
Shenoy,
A.
Hettinger,
S.
Fernandez,
J.
Blumenthal,
Valentina
Baez
(2021)
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study
British Journal of Haematology, 192
-
Chenguang
Shen,
Zhaoqin
Wang,
Fang
Zhao,
Yang
Yang,
Jin-xiu
Li,
Jing
Yuan,
Fuxiang
Wang,
Delin
Li,
Minghui
Yang,
L.
Xing,
Jinli
Wei,
Haixia
Xiao,
Yan
Yang,
J.
Qu,
L.
Qing,
Li
Chen,
Zhixiang
Xu,
Ling
Peng,
Yanjie
Li,
Haixia
Zheng,
Feng
Chen,
Kun-Hua
Huang,
Yujin
Jiang,
Dongjing
Liu,
Zheng
Zhang,
Yingxia
Liu,
Lei
Liu
(2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA
-
(
McGuireLW
ReddenWR
. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am J Public Health (N Y). 1918;8(10):741–744. doi:10.2105/ajph.8.10.74118009960)
McGuireLW
ReddenWR
. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am J Public Health (N Y). 1918;8(10):741–744. doi:10.2105/ajph.8.10.74118009960
McGuireLW
ReddenWR
. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am J Public Health (N Y). 1918;8(10):741–744. doi:10.2105/ajph.8.10.74118009960,
McGuireLW
ReddenWR
. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am J Public Health (N Y). 1918;8(10):741–744. doi:10.2105/ajph.8.10.74118009960
-
A.
Delamou,
N.
Haba,
A.
Marí-Saéz,
P.
Gallian,
M.
Ronse,
J.
Jacobs,
B.
Camara,
Kadio
Kadio,
Achille
Guemou,
Jean
Kolie,
Maaike
Crop,
P.
Chavarin,
C.
Jacquot,
C.
Lazaygues,
A.
Weggheleire,
L.
Lynen,
J.
Griensven
(2016)
Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea
The American Journal of Tropical Medicine and Hygiene, 95
-
S.
Flexner,
P.
Lewis
(1910)
EXPERIMENTAL POLIOMYELITIS IN MONKEYSEIGHTH NOTE: FURTHER CONTRIBUTIONS TO THE SUBJECTS OF IMMUNIZATION AND SERUM THERAPY
JAMA, 55
-
(
WuZ
McGooganJM
. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.264832091533)
WuZ
McGooganJM
. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.264832091533
WuZ
McGooganJM
. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.264832091533,
WuZ
McGooganJM
. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.264832091533
-
L.
Mcguire,
W.
Redden
(1918)
THE USE OF CONVALESCENT HUMAN SERUM IN INFLUENZA PNEUMONIA-A PRELIMINARY REPORT.
American journal of public health, 8 10
-
J.
Kakuturu,
C.
McCluskey,
Francis
Casey,
S.
Çiçek,
J.
Hayanga
(2021)
Extracorporeal membrane oxygenation to treat a 15-year-old patient with severe coronavirus disease 2019 (COVID-19) respiratory failure
JTCVS Techniques, 7
-
S.
Klassen,
J.
Senefeld,
Patrick
Johnson,
R.
Carter,
C.
Wiggins,
S.
Shoham,
B.
Grossman,
J.
Henderson,
J.
Musser,
E.
Salazar,
W.
Hartman,
Nicole
Bouvier,
Sean
Liu,
L.
Pirofski,
S.
Baker,
N.
Helmond,
R.
Wright,
D.
Fairweather,
K.
Bruno,
Zhen
Wang,
N.
Paneth,
A.
Casadevall,
M.
Joyner
(2021)
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
Mayo Clinic Proceedings, 96
-
S.
Kemp,
D.
Collier,
R.
Datir,
I.
Ferreira,
S.
Gayed,
A.
Jahun,
M.
Hosmillo,
C.
Rees-Spear,
P.
Mlcochova,
Ines
Lumb,
D.
Roberts,
Anita
Chandra,
Nigel
Temperton,
K.
Sharrocks,
E.
Blane,
J.
Briggs,
M.
Gils,
K.
Smith,
J.
Bradley,
C.
Smith,
R.
Doffinger,
L.
Ceron-Gutierrez,
G.
Barcenas-Morales,
D.
Pollock,
R.
Goldstein,
A.
Smielewska,
J.
Skittrall,
T.
Gouliouris,
I.
Goodfellow,
E.
Gkrania-Klotsas,
C.
Illingworth,
L.
McCoy,
R.
Gupta
(2020)
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
medRxiv
-
Ling
Li,
Wei
Zhang,
Yu
Hu,
Xunliang
Tong,
Shangen
Zheng,
Juntao
Yang,
Yujie
Kong,
L.
Ren,
Qing
Wei,
H.
Mei,
Caiying
Hu,
Cuihua
Tao,
Ruoyu
Yang,
Jue
Wang,
Yongpei
Yu,
Yong
Guo,
Xiaoxiong
Wu,
Zhihua
Xu,
Li-Qin
Zeng,
N.
Xiong,
Lifeng
Chen,
Juan
Wang,
N.
Man,
Yu
Liu,
Haixia
Xu,
E.
Deng,
Xuejun
Zhang,
Chenyue
Li,
Conghui
Wang,
Shisheng
Su,
Linqi
Zhang,
Jianwei
Wang,
Yanyun
Wu,
Zhong
Liu
(2020)
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
JAMA
-
(
ErkurtMA
SariciA
Berberİ
Kukuİ
KayaE
ÖzgülM
. Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern anatolia. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102867. doi:10.1016/j.transci.2020.102867)
ErkurtMA
SariciA
Berberİ
Kukuİ
KayaE
ÖzgülM
. Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern anatolia. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102867. doi:10.1016/j.transci.2020.102867
ErkurtMA
SariciA
Berberİ
Kukuİ
KayaE
ÖzgülM
. Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern anatolia. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102867. doi:10.1016/j.transci.2020.102867,
ErkurtMA
SariciA
Berberİ
Kukuİ
KayaE
ÖzgülM
. Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern anatolia. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2020;59(5):102867. doi:10.1016/j.transci.2020.102867
-
(
LiL
ZhangW
HuY
, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.1004432492084)
LiL
ZhangW
HuY
, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.1004432492084
LiL
ZhangW
HuY
, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.1004432492084,
LiL
ZhangW
HuY
, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.1004432492084
-
(
RogersR
ShehadehF
MylonaEK
, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021 Jul 1;73(1):e208–e214. 10.1093/cid/ciaa1548.)
RogersR
ShehadehF
MylonaEK
, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021 Jul 1;73(1):e208–e214. 10.1093/cid/ciaa1548.
RogersR
ShehadehF
MylonaEK
, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021 Jul 1;73(1):e208–e214. 10.1093/cid/ciaa1548.,
RogersR
ShehadehF
MylonaEK
, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021 Jul 1;73(1):e208–e214. 10.1093/cid/ciaa1548.
-
H.
Abolghasemi,
P.
Eshghi,
A.
Cheraghali,
A.
Fooladi,
Farzaneh
Moghaddam,
S.
Imanizadeh,
Matin
Maleki,
Mohammad
Ranjkesh,
M.
Rezapour,
Ali
Bahramifar,
B.
Einollahi,
M.
Hosseini,
N.
Jafari,
Mohamad
Nikpouraghdam,
N.
Sadri,
M.
Tazik,
S.
Sali,
Shamsi
Okati,
E.
Askari,
P.
Tabarsi,
J.
Aslani,
E.
Sharifipour,
M.
Jarahzadeh,
Nastaran
Khodakarim,
M.
Salesi,
Ramezan
Jafari,
Samira
Shahverdi
(2020)
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
Transfusion and Apheresis Science, 59
-
(
KempSA
CollierDA
DatirR
, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv [Preprint]. 2020 Dec 29:2020.12.05.20241927. doi:10.1101/2020.12.05.20241927)
KempSA
CollierDA
DatirR
, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv [Preprint]. 2020 Dec 29:2020.12.05.20241927. doi:10.1101/2020.12.05.20241927
KempSA
CollierDA
DatirR
, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv [Preprint]. 2020 Dec 29:2020.12.05.20241927. doi:10.1101/2020.12.05.20241927,
KempSA
CollierDA
DatirR
, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv [Preprint]. 2020 Dec 29:2020.12.05.20241927. doi:10.1101/2020.12.05.20241927
-
Ralph
Rogers,
F.
Shehadeh,
E.
Mylona,
Josiah
Rich,
Marguerite
Neill,
Francine
Touzard-Romo,
Sara
Geffert,
Jerome
Larkin,
Jeffrey
Bailey,
Shaolei
Lu,
Joseph
Sweeney,
Eleftherios
Mylonakis
(2020)
Convalescent plasma for patients with severe COVID-19: a matched cohort study
medRxiv
-
F.
Zhou,
Ting
Yu,
R.
Du,
Guohui
Fan,
Y.
Liu,
Zhibo
Liu,
J.
Xiang,
Ye-ming
Wang,
Bin
Song,
Xiaoying
Gu,
Lulu
Guan,
Yuan
Wei,
Hui
Li,
Xudong
Wu,
Jiuyang
Xu,
Shengjin
Tu,
Yi
Zhang,
Hua
Chen,
B.
Cao
(2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Lancet (London, England), 395
-
S.
Alsharidah,
M.
Ayed,
Reem
Ameen,
Fatma
Alhuraish,
Najat
Rouheldeen,
Farah
Alshammari,
A.
Embaireeg,
Mariam
Almelahi,
M.
Adel,
Mohammed
Dawoud,
Mohammad
Aljasmi,
Nashmi
Alshammari,
A.
Alsaeedi,
W.
Al-Adsani,
H.
Arian,
H.
Awad,
Humoud
Alenezi,
Azeez
Alzafiri,
E.
Gouda,
Mohammad
Almehanna,
Salem
Alqahtani,
Abdulrahman
Alshammari,
M.
Askar
(2020)
COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study
International Journal of Infectious Diseases, 103
-
(
DelamouA
HabaNY
Mari-SaezA
, et al. Organizing the donation of convalescent plasma for a therapeutic clinical trial on ebola virus disease: the experience in guinea. Am J Trop Med Hyg. 2016;95(3):647–653. doi:10.4269/ajtmh.15-089027430546)
DelamouA
HabaNY
Mari-SaezA
, et al. Organizing the donation of convalescent plasma for a therapeutic clinical trial on ebola virus disease: the experience in guinea. Am J Trop Med Hyg. 2016;95(3):647–653. doi:10.4269/ajtmh.15-089027430546
DelamouA
HabaNY
Mari-SaezA
, et al. Organizing the donation of convalescent plasma for a therapeutic clinical trial on ebola virus disease: the experience in guinea. Am J Trop Med Hyg. 2016;95(3):647–653. doi:10.4269/ajtmh.15-089027430546,
DelamouA
HabaNY
Mari-SaezA
, et al. Organizing the donation of convalescent plasma for a therapeutic clinical trial on ebola virus disease: the experience in guinea. Am J Trop Med Hyg. 2016;95(3):647–653. doi:10.4269/ajtmh.15-089027430546
-
M.
Joyner,
R.
Wright,
D.
Fairweather,
J.
Senefeld,
K.
Bruno,
S.
Klassen,
R.
Carter,
A.
Klompas,
C.
Wiggins,
J.
Shepherd,
R.
Rea,
E.
Whelan,
A.
Clayburn,
Matthew
Spiegel,
Patrick
Johnson,
E.
Lesser,
S.
Baker,
K.
Larson,
J.
Ripoll,
K.
Andersen,
D.
Hodge,
K.
Kunze,
M.
Buras,
M.
Vogt,
V.
Herasevich,
J.
Dennis,
R.
Regimbal,
P.
Bauer,
J.
Blair,
C.
Buskirk,
J.
Winters,
J.
Stubbs,
N.
Paneth,
N.
Verdun,
P.
Marks,
A.
Casadevall
(2020)
Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.
The Journal of clinical investigation
-
(
ChenL
XiongJ
BaoL
ShiY
. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-932113510)
ChenL
XiongJ
BaoL
ShiY
. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-932113510
ChenL
XiongJ
BaoL
ShiY
. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-932113510,
ChenL
XiongJ
BaoL
ShiY
. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-932113510
-
(
OmraniAS
ZaqoutA
BaiouA
, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol. 2021;93(3):1678–1686. doi:10.1002/jmv.2653732965715)
OmraniAS
ZaqoutA
BaiouA
, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol. 2021;93(3):1678–1686. doi:10.1002/jmv.2653732965715
OmraniAS
ZaqoutA
BaiouA
, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol. 2021;93(3):1678–1686. doi:10.1002/jmv.2653732965715,
OmraniAS
ZaqoutA
BaiouA
, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol. 2021;93(3):1678–1686. doi:10.1002/jmv.2653732965715
-
Long
Chen,
Jing
Xiong,
Lei
Bao,
Yuan
Shi
(2020)
Convalescent plasma as a potential therapy for COVID-19
The Lancet. Infectious Diseases, 20